Novartis bags Mesoblast's stem cell therapy for ARDS, including in Covid-19, in a deal worth up to $1.2B
Novartis has licensed a new stem cell therapy from Mesoblast, just weeks after the FDA rejected the Australian biotech’s pitch for an approval on a separate indication. The Swiss pharma announced Thursday afternoon it is partnering with Mesoblast $MESO to develop remestemcel-L for the treatment of acute respiratory distress syndrome,
Novartis bags Mesoblast's stem cell therapy for ARDS, including in Covid-19, in a deal worth up to $1.2B
Novartis has licensed a new stem cell therapy from Mesoblast, just weeks after the FDA rejected the Australian biotech’s pitch for an approval on a separate indication. The Swiss pharma announced Thursday afternoon it is partnering with Mesoblast $MESO to develop remestemcel-L for the treatment of acute respiratory distress syndrome,